{"id":"atorvastatin-aspirin-losartan-amlodipine","safety":{"commonSideEffects":[{"rate":"2-5","effect":"Muscle pain or myalgia"},{"rate":"5-10","effect":"Headache"},{"rate":"3-8","effect":"Dizziness"},{"rate":"5-15","effect":"Gastrointestinal upset"},{"rate":"2-8","effect":"Peripheral edema"},{"rate":"1-3","effect":"Bleeding or bruising"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atorvastatin inhibits HMG-CoA reductase to lower LDL cholesterol and reduce atherosclerotic plaque formation. Aspirin irreversibly inhibits cyclooxygenase to prevent platelet aggregation and thrombotic events. Losartan blocks angiotensin II type 1 receptors to reduce vasoconstriction and lower blood pressure. Amlodipine blocks L-type calcium channels in vascular smooth muscle to cause vasodilation and further reduce blood pressure and improve myocardial oxygen supply.","oneSentence":"This is a fixed-dose combination of four cardiovascular agents that work synergistically to reduce cholesterol, prevent thrombosis, lower blood pressure, and improve coronary blood flow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:35.820Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Secondary prevention of cardiovascular events in patients with coronary artery disease or high cardiovascular risk"},{"name":"Hypertension management in patients requiring lipid-lowering and antiplatelet therapy"}]},"trialDetails":[{"nctId":"NCT05479097","phase":"NA","title":"Feasibility Study of a Novel mHealth Application to Enable Community Health Workers to Manage","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2023-02-06","conditions":"Hypertension","enrollment":32},{"nctId":"NCT00231803","phase":"NA","title":"The Canadian Prevention of Renal and Cardiovascular Endpoints Trial","status":"COMPLETED","sponsor":"Brendan Barrett","startDate":"2005-04","conditions":"Chronic Kidney Disease","enrollment":474},{"nctId":"NCT00805311","phase":"PHASE4","title":"Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis","status":"TERMINATED","sponsor":"Russian Cardiology Research and Production Center","startDate":"2009-04","conditions":"Carotid Artery Stenosis, Atherosclerosis, Stroke","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"atorvastatin, aspirin, losartan, amlodipine","genericName":"atorvastatin, aspirin, losartan, amlodipine","companyName":"Russian Cardiology Research and Production Center","companyId":"russian-cardiology-research-and-production-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a fixed-dose combination of four cardiovascular agents that work synergistically to reduce cholesterol, prevent thrombosis, lower blood pressure, and improve coronary blood flow. Used for Secondary prevention of cardiovascular events in patients with coronary artery disease or high cardiovascular risk, Hypertension management in patients requiring lipid-lowering and antiplatelet therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}